Siponimod
Sponsors
Hadassah Medical Organization, Novartis Pharmaceuticals, Biogen, St. Joseph's Hospital and Medical Center, Phoenix
Conditions
Active Secondary Progressive Multiple SclerosisAdvancing Multiple SclerosisAlzheimer DiseaseCognitive Impairment, MildHealthyMCI With Increased Risk for Alzheimer DiseaseMild Alzheimer DiseaseMultiple Sclerosis
Phase 2
Phase 3
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
CompletedNCT03623243
Start: 2019-02-14End: 2022-07-06Updated: 2024-06-20
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Active, not recruitingNCT04926818
Start: 2021-10-05End: 2031-02-28Updated: 2026-05-14
Unknown Phase
Determinants of Warfarin Metabolism
RecruitingNCT00162474
Start: 2003-09-01End: 2030-12-01Target: 1000Updated: 2026-04-21
Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
NCT04540861
Updated: 2025-12-04
Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study
TerminatedNCT04895202
Start: 2021-11-19End: 2022-12-20Updated: 2023-08-29
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
RecruitingNCT04933552
Start: 2021-12-15End: 2032-05-31Target: 867Updated: 2024-05-16
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
CompletedNCT05376579
Start: 2022-06-17End: 2025-07-22Updated: 2026-05-19
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
RecruitingNCT05688436
Start: 2021-09-24End: 2031-01-17Target: 1178Updated: 2025-10-17